Novo Nordisk reports Phase 2 results for zenagamtide, an amylin-pathway medicine, in type 2 diabetes
OtherP1Primary public evidenceSponsor press release
A Novo Nordisk release dated 6 June 2026 reported a 36-week Phase 2 trial of zenagamtide in 262 adults with type 2 diabetes. At the 40 mg dose the sponsor reported an A1C reduction of 1.71 percentage points and a body weight reduction of 14.6%, against 0.14 points and 2.1% with placebo.
-1.71 vs -0.14
A1C change in percentage points at 36 weeks, 40 mg vs placebo
-14.6% vs -2.1%
Body weight change at 36 weeks, 40 mg vs placebo
Background and context
What the registry shows next
ClinicalTrials.gov lists a Novo Nordisk Phase 3 program for zenagamtide. In type 2 diabetes, AMBITION 7 compares once-weekly zenagamtide with once-daily insulin glargine in 1,778 adults with type 2 diabetes and increased cardiovascular risk. It is recruiting, started in August 2026, and has primary completion registered for July 2028. In obesity, AMAZE 7 compares once-weekly zenagamtide with semaglutide in 650 adults and is also recruiting.
How to read this against the announcement
The Phase 2 figures on this page come from a company release. The Phase 3 records describe designs and plans only. They contain no efficacy findings, so they cannot confirm or revise what the Phase 2 release reported.
Trial records: ClinicalTrials.gov NCT07797335 (AMBITION 7) and NCT07668414 (AMAZE 7), read on 2026-10-15.
